Talphera Hits Milestone in Nephro CRRT Study, Strengthens Financial Position
In a significant development, Talphera, a leading biotechnology company, has announced that its Nephro CRRT study has reached the 50% enrollment milestone. This achievement, along with the satisfaction of certain conditions, triggered the closing of the third tranche of the company's March 2025 financing, generating gross proceeds of $4.1 million.
According to Vince Angotti, Chief Executive Officer at Talphera, the company had cash and investments of $20.4 million as of December 31st. This sum, combined with the remaining tranches, should provide runway through a potential FDA approval of Niyad next year. The CEO expressed confidence in the company's financial position, stating that they expect to complete enrollment of the NEPHRO CRRT study later this year and file the PMA within about 3 months after study completion.
The Nephro CRRT study is a registrational trial designed to evaluate the efficacy and safety of Talphera's nafamostat in continuous renal replacement therapy (CRRT). CRRT is a specific type of dialysis that runs for 24 hours on a slow flow, continuing on average between 5 and 7 days while the patient is in the intensive care unit. The study aims to address an unmet need in anticoagulation for the CRRT circuit.
Dr. Shakil Aslam, Talphera's Chief Medical Officer, highlighted the importance of finding a reliable and effective anticoagulant for CRRT. He noted that each hospital currently has a different protocol for achieving uninterrupted therapy, with some physicians opting not to use an anticoagulant at all due to concerns about current options.
Talphera's CEO emphasized that the company is committed to providing innovative solutions for critical care therapies like CRRT. With the Nephro CRRT study making progress and the financial position strengthened, Talphera is well-positioned to move forward with its plans, including filing a PMA within the next few months.
As the Nephro CRRT study continues to enroll patients and generate data, investors and analysts will be watching closely for updates on the company's progress. With a strong financial foundation in place, Talphera is poised to capitalize on its unique offerings and drive growth in the critical care market.
